Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895436 | 0.87 | GABRA5 (0.42) | GABRA5HDAC3HDAC2ABL1DGAT2 | |
| SCHEMBL9896404 | 0.86 | WNT3A (0.38) | GABRA5HDAC3HDAC2WNT3A | |
| SCHEMBL9947560 | 0.85 | GABRA5 (0.40) | GABRA5ABL1CYP1A2EGLN1 | |
| SCHEMBL9894861 | 0.84 | PDE4B (0.43) | GABRA5EGLN1 | |
| SCHEMBL9894568 | 0.84 | GABRA5 (0.39) | GABRA5HDAC3HDAC2NTRK1GLA | |
| SCHEMBL9894802 | 0.84 | MAPK14 (0.43) | GABRA5 | |
| SCHEMBL9895028 | 0.84 | GABRA5 (0.49) | GABRA5DGAT2EGLN1 | |
| SCHEMBL9895430 | 0.84 | GABRA5 (0.44) | GABRA5HDAC3HDAC2GLAHTT | |
| SCHEMBL9895060 | 0.83 | KDM5A (0.36) | EGLN1RAB9A | |
| SCHEMBL9895403 | 0.83 | RAB9A (0.45) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | claimed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | claimed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | claimed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | claimed |
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | GABRA5, GABRA1, GABRB1 | GABRA5 1/4885HDAC3 433/4885HDAC2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.